Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1981 Aug;12(2):111–115. doi: 10.1111/j.1365-2125.1981.tb01188.x

A pharmacokinetic and tolerance study of Ro13-9904, a new cephalosporin antibiotic.

M E Pickup, H A Bird, J R Lowe, L Lees, V Wright
PMCID: PMC1401870  PMID: 6272830

Abstract

1 Six healthy male volunteers received a total of 2500 mg of a new cephalosporin antibiotic Ro13-9904 by intramuscular injection in five divided doses at intervals of 12 h. 2 No significant systemic side-effects were observed and this was confirmed haematologically and biochemically. 3 The drug was distributed following intramuscular injection reaching a mean peak plasma concentration of 55 micrograms ml-1 (range 46-66) 1 to 2 h after the first injection. 4 Monoexponential elimination of drug was demonstrated. No significant difference was recorded in the plasma half-life after the initial dose (mean 6.7 h) and at steady state (mean 6.7 h). The half-life is long compared with other cephalosporin antibiotics. 5 On the basis of the observed half-life, steady state should be reached within 48 h. A mean peak plasma concentration of 74 micrograms ml-1 (range 65-87) was recorded at steady state. Steady state plasma concentrations of Ro13-9904 with a dose of 500 mg every 13 h may be predicted from the pharmacokinetics of a single dose.

Full text

PDF
111

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Seddon M., Wise R., Gillett A. P., Livingston R. Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1980 Aug;18(2):240–242. doi: 10.1128/aac.18.2.240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Shannon K., King A., Warren C., Phillips I. In vitro antibacterial activity and susceptibility of the cephalosporin Ro 13-9904 to beta-lactamases. Antimicrob Agents Chemother. 1980 Aug;18(2):292–298. doi: 10.1128/aac.18.2.292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Tucker S. M., Boyd P. J., Thompson A. E., Price R. G. Automated assay of N-acetyl-beta-glucosaminidase in normal and pathological human urine. Clin Chim Acta. 1975 Jul 23;62(2):333–339. doi: 10.1016/0009-8981(75)90245-4. [DOI] [PubMed] [Google Scholar]
  4. Wise R., Gillett A. P., Andrews J. M., Bedford K. A. Ro 13-9904: A cephalosporin with a high degree of activity and broad antibacterial activity: an invitro comparative study. J Antimicrob Chemother. 1980 Sep;6(5):595–600. doi: 10.1093/jac/6.5.595. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES